메뉴 건너뛰기




Volumn 25, Issue 1, 2007, Pages 1-2

On the road to new drugs in acute myeloid leukemia

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CLORETAZINE; CYTARABINE; DAUNORUBICIN; HYDRAZINE DERIVATIVE; IDARUBICIN; MITOXANTRONE; PHOSPHOTRANSFERASE INHIBITOR; PROTEIN FARNESYLTRANSFERASE INHIBITOR; TROXACITABINE; UNCLASSIFIED DRUG; VASCULOTROPIN INHIBITOR; VNP 40101M;

EID: 34548488183     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2006.08.6462     Document Type: Editorial
Times cited : (4)

References (2)
  • 1
    • 34548533162 scopus 로고    scopus 로고
    • Phase I/II study of continuous-infusion troxacitabine in refractory acute myeloid leukemia
    • Roboz GJ, Giles FJ, Ritchie EK, et al: Phase I/II study of continuous-infusion troxacitabine in refractory acute myeloid leukemia. J Clin Oncol 25:10-15, 2007
    • (2007) J Clin Oncol , vol.25 , pp. 10-15
    • Roboz, G.J.1    Giles, F.J.2    Ritchie, E.K.3
  • 2
    • 33846413076 scopus 로고    scopus 로고
    • Cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, has significant activity in patients age 60 years or older with previously untreated acute myeloid leukemia
    • Giles F, Rizzieri D, Karp J, et al: Cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, has significant activity in patients age 60 years or older with previously untreated acute myeloid leukemia. J Clin Oncol 25:25-31, 2007
    • (2007) J Clin Oncol , vol.25 , pp. 25-31
    • Giles, F.1    Rizzieri, D.2    Karp, J.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.